# Avatrombopag Combined With IST as First-line Treatment for SAA

> **NCT05720234** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 53 (estimated)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** avatrombopag

## Key facts

- **NCT ID:** NCT05720234
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-10
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720234, "Avatrombopag Combined With IST as First-line Treatment for SAA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05720234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*